Real-world experience of treating relapsed or refractory diffuse large B-cell lymphoma with tisagenlecleucel in Hong Kong
Patients with
relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) have poor
outcomes with traditional therapies. However, phase 3 clinical trials of
tisagenlecleucel, a CD-19 directed chimeric antigen receptor T-cell (CAR-T)
therapy, have shown improved ORR, CR, PFS and OS in patients with r/r DLBCL,
giving hope to these patients. Long-term real-world data from Hong Kong has
also shown improved outcomes with tisagenlecleucel in these patients.
